DK1257526T3 - Anilin-afledte ligander til thyreoidea-receptoren - Google Patents

Anilin-afledte ligander til thyreoidea-receptoren

Info

Publication number
DK1257526T3
DK1257526T3 DK01903064T DK01903064T DK1257526T3 DK 1257526 T3 DK1257526 T3 DK 1257526T3 DK 01903064 T DK01903064 T DK 01903064T DK 01903064 T DK01903064 T DK 01903064T DK 1257526 T3 DK1257526 T3 DK 1257526T3
Authority
DK
Denmark
Prior art keywords
aniline
thyroid receptor
derived ligands
ligands
derived
Prior art date
Application number
DK01903064T
Other languages
Danish (da)
English (en)
Inventor
Minsheng Zhang
Todd Jason Friends
Dennis E Ryono
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of DK1257526T3 publication Critical patent/DK1257526T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/27—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an acyclic unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/74—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK01903064T 2000-02-17 2001-01-12 Anilin-afledte ligander til thyreoidea-receptoren DK1257526T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18322300P 2000-02-17 2000-02-17
PCT/US2001/001204 WO2001060784A1 (en) 2000-02-17 2001-01-12 Aniline-derived ligands for the thyroid receptor

Publications (1)

Publication Number Publication Date
DK1257526T3 true DK1257526T3 (da) 2005-09-12

Family

ID=22671959

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01903064T DK1257526T3 (da) 2000-02-17 2001-01-12 Anilin-afledte ligander til thyreoidea-receptoren

Country Status (30)

Country Link
US (2) US6800605B1 (hu)
EP (1) EP1257526B1 (hu)
JP (1) JP4629294B2 (hu)
KR (1) KR100740383B1 (hu)
CN (1) CN1216857C (hu)
AR (1) AR031094A1 (hu)
AT (1) ATE295348T1 (hu)
AU (2) AU2001230929B2 (hu)
BR (1) BR0108134A (hu)
CA (1) CA2400486C (hu)
CO (1) CO5271672A1 (hu)
CZ (1) CZ20022771A3 (hu)
DE (1) DE60110753T2 (hu)
DK (1) DK1257526T3 (hu)
EG (1) EG25009A (hu)
ES (1) ES2242723T3 (hu)
HK (1) HK1047925B (hu)
HU (1) HUP0301777A3 (hu)
IL (2) IL150449A0 (hu)
MX (1) MXPA02007929A (hu)
MY (1) MY124534A (hu)
NO (1) NO329639B1 (hu)
NZ (1) NZ520023A (hu)
PE (1) PE20020767A1 (hu)
PL (1) PL201790B1 (hu)
PT (1) PT1257526E (hu)
RU (1) RU2260586C2 (hu)
UY (1) UY26581A1 (hu)
WO (1) WO2001060784A1 (hu)
ZA (1) ZA200206072B (hu)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6664291B2 (en) 2000-03-31 2003-12-16 Pfizer, Inc. Malonamic acids and derivatives thereof as thyroid receptor ligands
DE10131462A1 (de) * 2001-06-29 2003-01-09 Bayer Ag Phenol-Derivate
US6806381B2 (en) 2001-11-02 2004-10-19 Bristol-Myers Squibb Company Process for the preparation of aniline-derived thyroid receptor ligands
EP1448512A1 (en) * 2001-11-17 2004-08-25 NeuroSearch A/S Prodrugs of antidepressants and their use for treating depressions
GB0208384D0 (en) * 2002-04-11 2002-05-22 Karobio Ab Novel compounds
WO2004066929A2 (en) * 2003-01-24 2004-08-12 Bristol-Myers Squibb Company Cycloalkyl containing anilide ligands for the thyroid receptor
TW200504021A (en) * 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
PT1660090E (pt) * 2003-08-14 2013-01-11 Array Biopharma Inc Análogos de quinazolina como inibidores de tirosina-cinases recetoras
US7371759B2 (en) * 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7829552B2 (en) 2003-11-19 2010-11-09 Metabasis Therapeutics, Inc. Phosphorus-containing thyromimetics
GB0406378D0 (en) * 2004-03-22 2004-04-21 Karobio Ab Novel pharmaceutical compositions
MX2007014502A (es) 2005-05-26 2008-02-07 Metabasis Therapeutics Inc Tiromimeticos para el tratamiento de enfermedades del higado graso.
GB0606201D0 (en) * 2006-03-28 2006-05-10 Karobio Ab Improved crytalline material
GB0606212D0 (en) * 2006-03-28 2006-05-10 Karobio Ab Pharmaceutical compositions
US20070238770A1 (en) * 2006-04-05 2007-10-11 Bristol-Myers Squibb Company Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
GB0724478D0 (en) * 2007-12-14 2008-01-30 Karobio Ab Pharmaceutical compositions
US20090197947A1 (en) * 2008-02-01 2009-08-06 The Research Foundation Of State University Of New York Medicaments and methods for lowering plasma lipid levels and screening drugs
US8922530B2 (en) * 2010-01-06 2014-12-30 Apple Inc. Communicating stylus
EP2609910A1 (en) 2011-12-30 2013-07-03 Deva Holding Anonim Sirketi Formulations of eprotirome
EP2695611B1 (en) 2012-08-06 2014-10-01 Dr. August Wolff GmbH & Co. KG Arzneimittel Eprotirome for use in the prevention and/or treatment of hair disorders and compositions thereof
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
RS62408B1 (sr) * 2016-05-18 2021-10-29 Univ Oregon Health & Science Derivati sobetiroma
KR20190104524A (ko) 2016-11-21 2019-09-10 바이킹 테라퓨틱스 인코포레이티드 당원축적질환의 치료 방법
WO2018226604A1 (en) 2017-06-05 2018-12-13 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
EP3768690A4 (en) 2018-03-22 2021-11-24 Viking Therapeutics, Inc. CRYSTALLINE SHAPES AND METHOD FOR MAKING CRYSTALLINE SHAPES OF A COMPOUND
AU2019397067A1 (en) * 2018-12-12 2021-07-22 Autobahn Therapeutics, Inc. Novel thyromimetics
WO2020169069A1 (en) 2019-02-21 2020-08-27 Nanjing Ruijie Pharma Co., Ltd. Novel compounds and their uses as thyroid hormone receptor agonists
CN113784950A (zh) 2019-03-01 2021-12-10 速通医疗公司 新型拟甲状腺素药
US20230257367A1 (en) 2020-06-02 2023-08-17 Chengdu Kanghong Pharmaceutical Co., Ltd. Novel thyroid hormone beta receptor agonist
WO2023177667A1 (en) * 2022-03-16 2023-09-21 Brii Biosciences, Inc. Thyroid hormone receptor agonists

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1078582B (de) * 1958-10-29 1960-03-31 Hoechst Ag Verfahren zur Herstellung substituierter Thyropropionsaeuren
JPS6061747A (ja) * 1983-09-16 1985-04-09 Konishiroku Photo Ind Co Ltd 熱現像感光材料
ATE159515T1 (de) 1992-07-21 1997-11-15 Ciba Geigy Ag Oxamidsäure-derivate als hypocholesterämische mittel
GB9713739D0 (en) * 1997-06-27 1997-09-03 Karobio Ab Thyroid receptor ligands
CZ20013117A3 (cs) 1999-03-01 2002-06-12 Pfizer Products Inc. Oxamové kyseliny a jejich deriváty jako ligandy thyreoidního receptoru
DK1033364T3 (da) 1999-03-01 2005-06-06 Pfizer Prod Inc Cyanholdige oxamidsyrer og -derivater som thyroideareceptorligander
CO5160290A1 (es) 1999-03-29 2002-05-30 Novartis Ag Derivados de acido fenoxifeniloxamico sustituido .
DE60020786T2 (de) 1999-09-30 2006-03-23 Pfizer Products Inc., Groton 6-Azauracilderivate als Liganden der Thyroidrezeptoren
US6664291B2 (en) 2000-03-31 2003-12-16 Pfizer, Inc. Malonamic acids and derivatives thereof as thyroid receptor ligands
IL151376A0 (en) * 2000-03-31 2003-04-10 Pfizer Prod Inc Malonamic acids and derivatives thereof as thyroid receptor ligands
AU4884701A (en) * 2000-05-12 2001-11-20 Kissei Pharmaceutical Co. Ltd. Malonanilic acid derivatives, medicinal compositions containing the same and usethereof
JP4225791B2 (ja) * 2001-05-18 2009-02-18 キッセイ薬品工業株式会社 肝癌の予防または再発抑制剤
TW200504021A (en) * 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor

Also Published As

Publication number Publication date
BR0108134A (pt) 2003-09-30
PE20020767A1 (es) 2002-08-17
KR20020075799A (ko) 2002-10-05
KR100740383B1 (ko) 2007-07-16
EP1257526B1 (en) 2005-05-11
NO20023895L (no) 2002-10-16
US6800605B1 (en) 2004-10-05
AU3092901A (en) 2001-08-27
PL201790B1 (pl) 2009-05-29
DE60110753D1 (de) 2005-06-16
ES2242723T3 (es) 2005-11-16
HK1047925A1 (en) 2003-03-14
JP4629294B2 (ja) 2011-02-09
AU2001230929B2 (en) 2004-09-23
MXPA02007929A (es) 2003-02-10
HUP0301777A3 (en) 2010-09-28
JP2004500382A (ja) 2004-01-08
NO20023895D0 (no) 2002-08-16
UY26581A1 (es) 2001-09-28
MY124534A (en) 2006-06-30
ZA200206072B (en) 2004-02-11
NZ520023A (en) 2004-05-28
IL150449A (en) 2008-03-20
WO2001060784A1 (en) 2001-08-23
EG25009A (en) 2011-05-16
CN1418185A (zh) 2003-05-14
CA2400486A1 (en) 2001-08-23
AR031094A1 (es) 2003-09-10
RU2260586C2 (ru) 2005-09-20
PT1257526E (pt) 2005-09-30
US7109164B2 (en) 2006-09-19
CZ20022771A3 (cs) 2003-09-17
CO5271672A1 (es) 2003-04-30
HK1047925B (zh) 2005-11-11
ATE295348T1 (de) 2005-05-15
US20050032890A1 (en) 2005-02-10
DE60110753T2 (de) 2006-02-23
NO329639B1 (no) 2010-11-22
IL150449A0 (en) 2002-12-01
CA2400486C (en) 2011-01-11
PL366149A1 (en) 2005-01-24
CN1216857C (zh) 2005-08-31
RU2002123349A (ru) 2004-01-10
HUP0301777A2 (hu) 2003-09-29
EP1257526A1 (en) 2002-11-20

Similar Documents

Publication Publication Date Title
DK1257526T3 (da) Anilin-afledte ligander til thyreoidea-receptoren
NO20026280L (no) Melanokortin reseptor-ligander
MA25403A1 (fr) Ligandes de recepteur de melanocortine
NO20032585D0 (no) ABCA-1 forhöyende forbindelser
AU8066701A (en) Capsaicin receptor ligands
NO20026196L (no) Kinazolinditosylatsalt-forbindelser
DK1619192T3 (da) Arylkondeserede azapolycykliske forbindelser
AU2003225305A8 (en) Pyridine-based thyroid receptor ligands
IL157031A0 (en) Thyroid receptor ligands
EP1601641A4 (en) SUBSTITUTED ANILID BINDER FOR THE THYROID RECEPTOR
DE60101126D1 (de) Tintenstrahlaufzeichnungselement
DE69910997D1 (de) Azabzyclische 5ht1 rezeptor liganden
DK1164375T3 (da) Assay til antitransglutaminaseantistoffer
ITMI20000456V0 (it) Custodia perfezionata per rivoltella
DE60102606D1 (de) Tintenstrahlaufzeichnungselement
ATE372338T1 (de) Deshalogenverbindungen
DE50105246D1 (de) Winkel- bzw. schrägbohr-einrichtung
NO20031837D0 (no) Kalsilytiske forbindelser
NO20030303L (no) Kalsilytiske forbindelser
NO20023508L (no) Kalsilyttiske forbindelser
NO20030781D0 (no) Prodrugs til NMDA-reseptor-ligander
DE60111997D1 (de) Tintenstrahlaufzeichnungselement
DK1119543T3 (da) N-Aralkylaminotetraliner som ligander for neuropeptid Y Y5-receptoren
FI20000588A0 (fi) Paikannusjärjestelmä
DK199900248A (da) Betræk til vådliggere